Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy. By continuing to use this site without changing your settings you consent to our use of cookies in accordance with our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
You searched for:
Search

Search

Practice
 
Sub-Practice
 
Sector
 
Sub-Sector
 
Country
 
Language
 
1-10 of 31 results
Results per page: 
Sort by: 
​A&O, once again demonstrating our track record of acting on, and successfully completing, complex high-value transactions in a wide range of sectors and markets. A&O, once again demonstrating our track record of acting on, and successfully completing, complex high-value transactions in a wide
10 July 2018
http://www.allenovery.com/news/en-gb/articl … es-show-strength-of-AO’s-global-MA-team.aspx
Allen & Overy has advised science-based pharmaceutical company Grünenthal on its acquisition of AstraZeneca’s European rights to prescription Nexium and the global (excluding the US and Japan) rights . Allen & Overy has advised science-based pharmaceutical company Grünenthal on its acquisition of
30 October 2018
http://www.allenovery.com/news/en-gb/articl … -with-AstraZeneca-for-Nexium-and-Vimovo.aspx
The recovery in global M&A markets is developing a broader base according to Allen & Overy’s latest M&A Index. The recovery in global M&A markets is developing a broader base according to Allen & Overy’s latest M&A Index.
10 July 2014
http://www.allenovery.com/news/en-gb/articl … es-led-by-TMT-and-Life-Sciences-sectors.aspx
In January 2016, a year before the anticipated opening of the new Unified Patent Court, Allen & Overy’s patent litigators from seven of our European offices took part in two “mock” hearings before a fictional UPC court operating at our Brussels office.
08 February 2016
http://www.allenovery.com/news/en-gb/articl … trials-give-a-flavour-of-the-real-thing.aspx
Allen & Overy has advised the founders and shareholders of Walmark, Czech manufacturer of dietary supplements, OTC pharmaceuticals and other related products with subsidiaries in 10 other European countries, on the 50% capital entry by Mid Europa Partners, one of the leading private equity funds in
17 August 2012
http://www.allenovery.com/news/en-gb/articles/Pages/Walmark-Mid Europa.aspx
HONG KONG – Allen & Overy said today that Glenmark Pharmaceuticals Limited’s USD170 million convertible bond with a rare “resettable onward starting equity-linked” feature, points to the revival of the Indian convertible bond market following reduced volumes in the last two years.
12 July 2016
http://www.allenovery.com/news/en-gb/articl … rtible-bond-market-using-rare-structure.aspx
The The
31 January 2018
http://www.allenovery.com/news/en-gb/articl … -The-Lawyer's-Hot-100-listings-for-2018.aspx
Allen & Overy Casablanca advises KMR in the acquisition of Laureate SOMED Education Holding CASABLANCA - Allen & Overy (A&O) advised KMR Holding Pédagogique (KMR) in the acquisition through its wholly-owned subsidary Université Privée de Marrakech Pédagogique (UPM) of 100% of the share capital of
24 January 2018
http://www.allenovery.com/news/en-gb/articl … ion-of-Laureate-SOMED-Education-Holding.aspx
Allen & Overy has assisted its longstanding client Sanofi with providing successful arguments required for the registration of its trademark involving the distinctive shape of its Ibalgin pill in the Czech Republic. Allen & Overy has assisted its longstanding client Sanofi with providing successful
06 December 2017
http://www.allenovery.com/news/en-gb/articl … plication-success-in-the-Czech-Republic.aspx
Allen & Overy LLP has advised Cleanpart Group GmbH (Cleanpart), a portfolio company of Deutsche Beteiligungs AG (DBAG), on the sale if its healthcare business to VAMED, a service provider for hospitals that is majority-owned by Fresenius SE & Co. KGaA.
07 November 2017
http://www.allenovery.com/news/en-gb/articl … eim-Verkauf-ihres-Healthcare-Geschäfts-.aspx


  • Add comment (optional)